Method for determining sensitivity to an anticancer agent

Patent metadata

Field	Value
Publication number	US-9459254-B2
Application number	US-201013505143-A
Country	US
Kind code	B2
Filing date	Oct 29, 2010
Priority date	Oct 30, 2009
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.
The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, the peaks being determined by means of a mass spectrometer.

First claim

The invention claimed is:

1. A method for treating colorectal cancer in a subject in need thereof which comprises
(a) obtaining a biological sample from a subject having colorectal cancer;
(b) determining the absence or presence of at least one marker selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, in said biological sample obtained in (a) by mass spectrometry and then for each peak detected indicating the presence of said at least one marker determining the concentration of the marker corresponding to the peak detected;
(c) administering to said subject a anticancer agent selected from the group consisting of fluorouracil, SN-38, and irinotecan, or a salt thereof;
(d) obtaining a biological sample from said subject following said administering;
(e) determining the absence or presence of at least one marker selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 16,450 to 16,620, a protein or a fragment thereof which is detected as a peak at m/z of 22,080 to 22,310, and a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, in said biological sample obtained in (d) by mass spectrometry and then for each peak detected indicating the presence of said at least one marker determining the concentration of the marker corresponding to the peak detected;
(f) comparing the concentration of said at least one marker measured in (e) to the concentration of said at least one marker measured in (b) to determine whether said colorectal cancer is sensitive to said anticancer agent, wherein:
sensitivity is determined by measuring a concentration of protein A having a peak at m/z of 16,450 to 16,620 wherein when the concentration of protein A in (e) is greater than the concentration of protein A in (b) said subject is determined to have sensitivity to the anti-cancer agent,
sensitivity is determined by measuring a concentration of protein B having a peak at m/z of 22,080 to 22,310 wherein when the concentration of protein B in (e) is greater than the concentration of protein B in (b) said subject is determined to have sensitivity to the anti-cancer agent, and/or
sensitivity is determined by measuring a concentration of protein C having a peak at m/z of 17,100 to 17,270 wherein when the concentration of protein C in (e) is the same as or less than the concentration of protein C in (b) said subject is determined to have sensitivity to the anti-cancer agent
(g) continuing administration of said anti-cancer agent where said colorectal cancer is determined to be sensitive to said anti-cancer agent or discontinuing administration of said anti-cancer agent where said colorectal cancer is determined to not be sensitive to said anti-cancer agent,
wherein the concentration determination is by assessing mass spectrometry peak intensities of said markers.

2. The method according to claim 1 , wherein the biological sample is blood.

3. The method according to claim 1 , wherein the biological sample is serum.

4. The method according to claim 1 , wherein the anti-cancer agent is fluorouracil or a salt thereof.

5. The method according to claim 1 , wherein the anti-cancer agent is a combination of fluorouracil or a salt thereof with irinotecan, SN-38, or a salt thereof.

6. The method according to claim 1 , wherein the biological sample is plasma.

7. The method according to claim 1 , wherein the biological sample is a cancer tissue biopsy specimen.

8. The method according to claim 1 , wherein the biological sample is a cancer isolated preparation.

9. The determination method according to claim 1 , wherein the biological sample is feces.

10. The method according to claim 1 , wherein the biological sample is urine.

11. The method according to claim 1 , wherein the biological sample is ascitic fluid.

12. The method according to claim 1 , wherein the biological sample is pleural fluid.

13. The method according to claim 1 , wherein the biological sample is cerebrospinal fluid.

14. The method according to claim 1 , wherein the biological sample is expectoration.

15. The method according to claim 1 , wherein the anti-cancer agent is irinotecan or a salt thereof.

16. The method according to claim 1 , wherein the anti-cancer agent is SN-38 or a salt thereof.

17. The method according to claim 1 , wherein sensitivity is determined by measuring a concentration of protein A having a peak at m/z of 16,450 to 16,620 wherein when the concentration of protein A in (e) is greater than the concentration of protein A in (b) said subject is determined to have sensitivity to the anti-cancer agent.

18. The method according to claim 1 , wherein sensitivity is determined by measuring a concentration of protein B having a peak at m/z of 22,080 to 22,310 wherein when the concentration of protein B in (e) is greater than the concentration of protein B in (b) said subject is determined to have sensitivity to the anti-cancer agent.

19. The method according to claim 1 , wherein sensitivity is determined by measuring a concentration of protein C having a peak at m/z of 17,100 to 17,270 wherein when the concentration of protein C in (e) is the same as or less than the concentration of protein C in (b) said subject is determined to have sensitivity to the anti-cancer agent.

20. The method according to claim 1 , wherein said mass spectrometer is a surface-enhanced laser desorption/ionization time-of-flight mass spectrometer.

21. The method according to claim 1 , further comprising extracting intracellular proteins from the obtained biological sample prior to said determining.

22. The method according to claim 1 , wherein the extracted intracellular proteins are subjected to ProteinChip array analysis.

Assignees

• Tanigawara Yusuke
• Suzuki Sayo
• Irie Hidehiro
• Nishimuta Akito
• Suzuki Tetsuya
• Sugimoto Shinji
• Univ Keio
• Yakult Honsha Kk

Inventors

• Tanigawara Yusuke
• Suzuki Sayo
• Irie Hidehiro
• Nishimuta Akito
• Suzuki Tetsuya
• Sugimoto Shinji

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/575 Primary

  for cancer · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/4745

  condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title